Crick — Clinical Intelligence Platform

Testing effectiveness (Phase 2)Looking for participantsNCT06189495

What this trial is testing

A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease

Who this might be right for

Systemic Sclerosis Associated Interstitial Lung DiseaseRheumatoid Arthritis Associated Interstitial Lung Disease (RA-ILD)Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)

Changchun GeneScience Pharmaceutical Co., Ltd. 30

Results for “Rheumatoid Arthritis-Associated Interstitial Lung Disease”

A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease

Identification of Genes Associated With Lung Disease in Patients With Rheumatoid Arthritis

Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.

Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) Epidemiology Non-interventional Study (NIS)

Novel Biomarkers in Assessment of Interstitial Lung Disease Associated With Rheumatoid Arthritis Patients

Treatment Strategy for Patients With RA-ILD

Rituximab in Rheumatoid Arthritis Lung Disease

Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies

Interstitial Lung Diseases in Primary Sjogren's Syndrome

Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol.

Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)

Yellow Fever Vaccine in Patients With Rheumatic Diseases

AYLo - AutoimmunitY and Loss of y